Related Experiment Videos
Minimal residual disease as the target for immunotherapy of cancer
1Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Lancet (London, England)
|May 14, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The case history of Mr T.I. Terminal patient or still curable?
Immunology today·2014
WHO and health research--some personal reflections.
World health forum·1999
Awakening the global conscience: who will benefit from new vaccines in the 21st century?
Immunology and cell biology·1998
Host immunobiology and vaccine development.
Lancet (London, England)·1997
B lymphocyte physiology: the beginning and the end.
Ciba Foundation symposium·1997
Understanding peripheral arterial disease in the current era.
Lancet (London, England)·2026
Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead.
Lancet (London, England)·2026
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review.
Pharmaceuticals (Basel, Switzerland)·2026
Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy.
International journal of molecular sciences·2026